GlassScriptPhysician profile
Jason C Evans
NPI 1902825243
$104,191.78
in general payments reported to CMS, 2019-2025
23 companies · $27.95 in 2025
The $27.95 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70K · 2022: $33K · 2023: $46.12 · 2024: $1,140 · 2025: $27.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,140 · Food and Beverage: $74.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,140.00 |
| Food and Beverage | $74.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $35,442.33 | 2021-2022 | |
| Ucb, INC. | $32,115.87 | 2021-2024 | Bimzelx |
| Genzyme Corporation | $10,496.33 | 2021-2022 | |
| Abbvie INC. | $8,193.83 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $5,627.16 | 2021-2022 | |
| Janssen Biotech, INC. | $4,892.30 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $2,366.65 | 2021-2022 | |
| Lilly USA, LLC | $1,574.81 | 2021-2023 | Olumiant |
| Sun Pharmaceutical Industries INC. | $1,144.21 | 2021-2022 | |
| Incyte Corporation | $1,105.13 | 2021-2022 | |
| Leo Pharma INC. | $263.35 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $148.82 | 2021 | |
| Pfizer INC. | $129.67 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $120.12 | 2021 | |
| Epi Health, LLC | $119.00 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $116.82 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $85.00 | 2022 | |
| Amgen INC. | $78.75 | 2021 | |
| Vyne Pharmaceuticals INC. | $73.39 | 2021 | |
| Dendreon Pharmaceuticals LLC | $27.95 | 2025 | Provenge |
| Rochester Medical Corporation | $26.72 | 2021 | |
| Paratek Pharmaceuticals, INC. | $24.67 | 2021 | |
| Galderma Laboratories, L.P. | $18.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.